Previous 10 |
Galmed ( GLMD ) Q3 results: Revenues: $1.5M. More news on: Galmed Pharmaceuticals Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
Galmed (NASDAQ: GLMD ): Q3 GAAP EPS of -$0.05 beats by $0.12 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nona...
Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy f...
TEL AVIV, Israel , Sept. 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic ste...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: